← Eichor
Study identifier: NCT07362186 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Condition: Locally Advanced or Metastatic GC and GCJ Adenocarcinoma  ·  Sponsor: LaNova Medicines Limited

PhasePhase 3
Planned participants400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a phase III， Multicenter, Randomized study， evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.

This description comes directly from the study's public registry record.

Talk to the study team

Mengmeng Liu  ·  +86 13918118040  ·  mengmengliu@lanovamed.com

Paul Kong  ·  +86 13564682439  ·  paulkong@lanovamed.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Cancer HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07362186